2RT® Featured at the 2021 Meeting of the Association for Research in Vision and Ophthalmology
ASX Announcement General AlphaRET
3 May, 2021
Notice of Change of Interests of Substantial Holder
ASX Announcement General
30 Apr, 2021
First Patient Enrolled in MAGIC Clinical Trial for Glaucoma
ASX Announcement General iTrack
30 Apr, 2021
Five-Year Post-LEAD Review Shows Improvement in 2RT® Treatment Benefits for iAMD
ASX Announcement General AlphaRET
5 Mar, 2021
Clinical Trial to Assess Efficacy and Safety of iTrack™ in the Treatment of Mild to Moderate Glaucoma
ASX Announcement General iTrack
2 Mar, 2021
First Half FY2021 Accounts
ASX Announcement General
25 Feb, 2021
1HFY21: Growth in Glaucoma Surgical Devices Segment Despite Pandemic
ASX Announcement General
25 Feb, 2021
Notice of Upcoming Investor Call – First Half FY21 Results
ASX Announcement General
18 Feb, 2021
Notice of Change of Interests of Substantial holder
ASX Announcement General
14 Dec, 2020
Appendix 3G Issue of Options and Performance Rights
ASX Announcement General
9 Dec, 2020
Appendix 2A
ASX Announcement General
9 Dec, 2020
Poll Results Annual General Meeting 2020
ASX Announcement General
27 Nov, 2020
Chairman’s Address to Annual General Meeting
ASX Announcement General
27 Nov, 2020
PRESENTATION AND UPDATE, ANNUAL GENERAL MEETING 2020
ASX Announcement General
27 Nov, 2020
Strong Rebound for Glaucoma Surgical Device Sales in FY21
ASX Announcement General
25 Nov, 2020
2RT® Clinical Update: Sub-Study Analysis of LEAD Trial Demonstrates Improved Retinal Function Following Treatment with 2RT®
ASX Announcement General
16 Nov, 2020
Notice of Annual General Meeting
ASX Announcement General
26 Oct, 2020
Nova Eye Medical Establishes AlphaRET to Support Commercial Development of 2RT®
ASX Announcement AlphaRET
26 Oct, 2020
Date of AGM and Closing Date for Director Nominations
ASX Announcement General
8 Oct, 2020
Change in Substantial Holding (Australian Ethical)
ASX Announcement General
18 Sep, 2020
Change in Substantial Holding (Australian Ethical)
ASX Announcement General
10 Sep, 2020
New Director Appointment
ASX Announcement General
31 Aug, 2020
Notice of Upcoming Investor Call
ASX Announcement General
28 Aug, 2020
Nova Eye Records FY20 Net Profit After Tax of $35.7 Million
ASX Announcement General
28 Aug, 2020
Multicentre Study Highlights Surgical Efficiency of the Molteno3® Glaucoma Drainage Device
ASX Announcement Molteno3
5 Aug, 2020
Nova Eye Medical Completes Acquisition of Molteno Ophthalmology Assets
ASX Announcement General Molteno3
3 Aug, 2020
Payment to Shareholders of Capital Return and Dividend
ASX Announcement General
29 Jul, 2020
Updated Timetable for Capital Return & Dividend Payment
ASX Announcement General
16 Jul, 2020
Nova Eye Medical Expands Glaucoma Treatment Portfolio Through Acquisition of the Molteno3®
ASX Announcement General Molteno3
2 Jul, 2020
Appendix 3Z (Mangano)
ASX Announcement General
30 Jun, 2020
Appendix 3X (Spurling)
ASX Announcement General
30 Jun, 2020
Appendix 4E & Annual Report
ASX Announcement General
30 Jun, 2020
ASX ELX Completion Announcement
ASX Announcement General
30 Jun, 2020
For investor enquires please contact:
Dr. Tom Duthy
Nova Eye Medical Limited
W +61 402 493 727
tduthy@nova-eye.com
This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More
The cookies do not store any personalised information. Learn More